- Main
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET
- Flanders, Scott C;
- Kim, Janet;
- Wilson, Samuel;
- Braziunas, Jeffrey;
- Greenfield, Sheldon;
- Billimek, John;
- Lechpammer, Stanislav;
- Lin, Daniel W;
- Karsh, Lawrence;
- Quinn, David I;
- Shevrin, Daniel;
- Shore, Neal D;
- Symanowski, James T;
- Penson, David F
Published Web Location
https://doi.org/10.2217/fon-2017-0438Abstract
AIM: To validate the total illness burden index for prostate cancer (TIBI-CaP) in castration-resistant prostate cancer (CRPC) patients. PATIENTS & METHODS: Baseline comorbidity scores collected using the TIBI-CaP were compared with the baseline patient-reported health-related quality of life using the SF-12v2 and FACT-P questionnaires in 302 patients enrolled in the Treatment Registry for Outcomes in CRPC Patients (TRUMPET). RESULTS: Baseline TIBI-CaP scores were negatively correlated with all baseline SF-12v2 domain/composite (p < 0.001) and FACT-P subscale/total (p < 0.020) scores. There was a significant decreasing linear trend in SF12v2 and FACT-P scores over the categories based on TIBI-CaP quartiles of comorbidity burden (from 'least' to 'severe'). CONCLUSION: The TIBI-CaP is a valid measure of comorbidity burden in patients with CRPC in the real world.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.